June 2025, From the Field
On May 12, 2025, the U.S. and China significantly rolled back tariffs on each other’s goods for an initial 90-day period. The U.S. reduced tariffs on Chinese goods from 145% to 30%, while China cut retaliatory tariffs on U.S. goods from 125% to 10% for the period. Additionally, President Donald Trump’s revised executive order lowered tariffs on small packages valued under USD 800 from 120% to 54%. While further developments in trade talks are expected ahead, the truce was well received by the markets, with the MSCI China Index climbing 17% since April 7, 2025, lifting year-to-date returns to 15% (as of April 16, 2025).
"Regardless of the outcome of the trade deal, several trends are emerging, poised to reshape the global economic landscape…."
At the expiry of the 90-day window, we might see further escalation or de‑escalation. Regardless of the outcome of the trade deal, several trends are emerging, poised to reshape the global economic landscape and redefine investment opportunities.
Past performance is not a guarantee or a reliable indicator of future results.
Index performance is for illustrative purposes only and is not indicative of any specific investment. Investors cannot invest directly in an index.
Sources: MSCI (see Additional Disclosures), returns in USD. Financial data and analytics provider, FactSet. Copyright 2025 FactSet. All Rights Reserved.
As of April 30, 2025.
Sources: MSCI (see Additional Disclosures), Goldman Sachs Global Investment Research. Financial data and analytics provider, FactSet. Copyright 2025 FactSet. All Rights Reserved.
The U.S. is advancing its reindustrialization agenda, with tariff policies as a cornerstone. This strategy prioritizes strategic sectors such as semiconductors, electric vehicles, pharmaceuticals, steel, and shipbuilding. As a result, global supply chains in these industries are undergoing significant disruption and reconfiguration. The highly integrated, globalized supply chain model is giving way to a more regionalized yet interconnected framework. This shift presents challenges for all economies, but those with robust domestic markets and comprehensive industrial ecosystems are better equipped to adapt.
With lingering uncertainties from tariffs, it’s helpful to assess their potential impact on the Chinese economy.
Over the past decade, China has implemented proactive measures to mitigate external pressures. The Belt and Road Initiative has broadened access to global markets, diversifying trade partnerships, while the “dual circulation” strategy has fortified domestic economic resilience. Additionally, breakthroughs in critical technologies have eased supply‑side bottlenecks, and deleveraging in the financials and real estate sectors has reduced systemic risks, positioning China to better absorb potential shocks.
The economic impact from tariffs is moderated by China’s reduced reliance on U.S. markets. In 2024, exports to the U.S. (including re-exports) accounted for approximately 3% of China’s gross domestic product (GDP), down from 6% in 2010, reflecting a significant shift in trade dynamics.
At the corporate level, the impact of tariff escalation is limited for most Chinese firms, with U.S. exports comprising only around 1% of the average revenue of listed companies—one of the lowest U.S. exposures globally. Escalation may exacerbate slower economic growth, but firms are adapting by accelerating globalization strategies.
Since 2018, many have pivoted from export-focused models to globalized operations, a trend likely to intensify. Companies with advanced technologies and operational agility are well placed to seize opportunities, even in a volatile trade environment, supporting long-term equity resilience.
"Enhancing domestic consumption aligns with China’s internal needs…."
2024 annual data.
Sources: MSCI (see Additional Disclosures), Goldman Sachs Global Investment Research. Financial data and analytics provider, FactSet. Copyright 2025 FactSet. All Rights Reserved.
Companies with forward-looking strategies and flexible approaches stand to gain market share as the market evolves. Staying calm and conducting objective fundamental analysis can help investors uncover undervalued investment opportunities in China with significant potential.
1Source: China Pharmaceutical Industry Research Development Association. As of April 5, 2025.
Additional Disclosures
Financial data and analytics provider FactSet. Copyright 2025 FactSet. All Rights Reserved.
MSCI and its affiliates and third-party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.
Important Information
This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a guarantee or a reliable indicator of future results. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.
The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.
Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass.
The views contained herein are as of June 2025 and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.
The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.
Australia—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. For Wholesale Clients only.
Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to non‑individual Accredited Investors and non-individual Permitted Clients as defined under National Instrument 45-106 and National Instrument 31-103, respectively. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.
EEA—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.
New Zealand—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.
Switzerland—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.
UK—This material is issued and approved by T. Rowe Price International Ltd, Warwick Court, 5 Paternoster Square, London EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.
USA—Issued in the USA by T. Rowe Price Associates, Inc., 1307 Point Street, Baltimore, MD 21231, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.
© 2025 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, the Bighorn Sheep design, and related indicators (see troweprice.com/ip) are trademarks of T. Rowe Price Group, Inc. All other trademarks are the property of their respective owners.